- Home
- EVAX vs EYEN Comparison
EVAX vs EYEN Comparison
Compare EVAX & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- EYEN
- Stock Information
- Founded
- EVAX 2008
- EYEN 2014
- Country
- EVAX Denmark
- EYEN United States
- Employees
- EVAX N/A
- EYEN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- EYEN Health Care
- Exchange
- EVAX Nasdaq
- EYEN Nasdaq
- Market Cap
- EVAX 8.7M
- EYEN 9.2M
- IPO Year
- EVAX 2021
- EYEN 2018
- Fundamental
- Price
- EVAX $2.41
- EYEN $0.05
- Analyst Decision
- EVAX Strong Buy
- EYEN Hold
- Analyst Count
- EVAX 2
- EYEN 4
- Target Price
- EVAX $11.00
- EYEN $2.00
- AVG Volume (30 Days)
- EVAX 250.1K
- EYEN 48.4M
- Earning Date
- EVAX 10-31-2024
- EYEN 03-17-2025
- Dividend Yield
- EVAX N/A
- EYEN N/A
- EPS Growth
- EVAX N/A
- EYEN N/A
- EPS
- EVAX N/A
- EYEN N/A
- Revenue
- EVAX $3,295,000.00
- EYEN $31,832.00
- Revenue This Year
- EVAX $4,845.21
- EYEN $23,413.60
- Revenue Next Year
- EVAX $30.30
- EYEN $400.98
- P/E Ratio
- EVAX N/A
- EYEN N/A
- Revenue Growth
- EVAX N/A
- EYEN 2557.10
- 52 Week Low
- EVAX $2.38
- EYEN $0.05
- 52 Week High
- EVAX $68.05
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- EVAX 23.50
- EYEN 34.14
- Support Level
- EVAX $2.38
- EYEN $0.05
- Resistance Level
- EVAX $3.90
- EYEN $0.09
- Average True Range (ATR)
- EVAX 0.51
- EYEN 0.02
- MACD
- EVAX -0.05
- EYEN -0.00
- Stochastic Oscillator
- EVAX 2.72
- EYEN 2.50
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.